Relationship between gene expression and enhancement in glioblastoma multiforme: Exploratory DNA microarray analysis

Radiology

Volumn 249, Issue 1, 2008, Pages 268-277

  Pope, Whitney B ^a   Chen, Jenny H ^a   Dong, Jun ^a   Carlson, Marc R J ^a   Perlina, Alla ^a   Cloughesy, Timothy F ^a   Liau, Linda M ^a   Mischel, Paul S ^a   Nghiemphu, Phioanh ^a   Lai, Albert ^a   Nelson, Stanley F ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GADODIAMIDE; GADOLINIUM; MEMBRANE PROTEIN; OLIGODENDROCYTE TRANSCRIPTION FACTOR 2; PENTRAXIN; PROTEIN ZO 2; TRANSCRIPTION FACTOR MASH1; UNCLASSIFIED DRUG; VASCULOTROPIN; ASCL1 PROTEIN, HUMAN; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; C REACTIVE PROTEIN; NERVE PROTEIN; NEURONAL PENTRAXIN; OLIG2 PROTEIN, HUMAN; VASCULOTROPIN A; ZONULA OCCLUDENS 2 PROTEIN;

ARTICLE; CANCER SURVIVAL; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DNA MICROARRAY; GENE EXPRESSION; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIOMA; PRIORITY JOURNAL; TUMOR BIOPSY; BRAIN TUMOR; GENE EXPRESSION REGULATION; GENETICS; MORTALITY;

BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; BRAIN NEOPLASMS; C-REACTIVE PROTEIN; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; MAGNETIC RESONANCE IMAGING; MEMBRANE PROTEINS; NERVE TISSUE PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 53749087689     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.2491072000     Document Type: Article

References (39)

1. Rees JH, Smirniotopoulos JG, Jones RV, Wong K. Glioblastoma multiforme: radiologic-pathologic correlation. RadioGraphics 1996;16:1413-1438.
2. Pope WB, Sayre J, Perlina A, Villablanca JP, Mischel PS, Cloughesy TF. MR imaging correlates of survival in patients with high-grade gliomas. AJNR Am J Neuroradiol 2005;26: 2466-2474.
3. Arjona D, Rey JA, Taylor SM. Early genetic changes involved in low-grade astrocytic tumor development. Curr Mol Med 2006;6: 645-650.
4. Cohen-Gadol AA, DiLuna ML, Bannykh SI, Piepmeier JM, Spencer DD. Non-enhancing de novo glioblastoma: report of two cases. Neurosurg Rev2004;27:281-285.
5. Hobbs SK, Shi G, Homer R, Harsh G, Atlas SW, Bednarski MD. Magnetic resonance image-guided proteonomics of human glioblas- toma multiforme. J Magn Reson Imaging 2003;18:530-536.
6. Shai R, Shi T, Kremen TJ, et al. Gene expression profiling identifies molecular subtypes of gliomas. Oncogene 2003;22:4918- 4923. [Published correction appears in Oncogene 2006;25:4256.]
7. Freije WA, Castro-Vargas FE, Fang Z, et al. Gene expression profiling of gliomas strongly predicts survival. Cancer Res 2004;64:6503-6510.
8. Fleiss JL, Levin B, Paik MC. Statistical methods for rates and proportions. New York, NY: Wiley, 1981.
9. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
10. Cox DR, Oakes D. Analysis of survival data. New York, NY: Chapman and Hall, 1990.
11. Papadopoulos MC, Saadoun S, Binder DK, Manley GT, Krishna S, Verkman AS. Molecular mechanisms of brain tumor edema. Neuroscience 2004;129:1011-1020.
12. Fischer I, Gagner JP, Law M. Angiogenesis in gliomas: biology and molecular pathophysiology. Brain Pathol 2005;15:297-310.
13. Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT. Angiogenesis in brain tumours. Nat Rev Neurosci 2007;8: 610-622.
14. Rome C, Arsaut J, Taris C, Couillaud F, LoiseauH. MMP-7 (matrilysin)expressionin human brain tumors. Mol Carcinog 2007;46: 446-452.
15. Shiomi T, Okada Y. MT1-MMP and MMP-7 ininvasionand metastasis ofhumancancers. Cancer Metastasis Rev 2003;22:145-152.
16. Nakamura H, Fujii Y, Inoki I, et al. Brevican is degraded by matrix metalloproteinases and aggrecanase-1 (ADAMTS4) at different sites. J Biol Chem 2000;275:38885-38890.
17. Nakada M, Miyamori H, Kita D. Human glioblastomas overexpress ADAMTS-5 that degrades brevican. Acta Neuropathol 2005; 110:239-246.
18. Goldbrunner RH, Bernstein JJ, Tonn JC. Cell-extracellular matrix interaction in glioma nvasion. Acta Neurochirurg (Wien) 1999;141:295-305.
19. Mokhtari K, Paris S, Aguirre-Cruz L, et al. Olig2 expression, GFAP, p53 and 1p loss analysis contribute to glioma subclassifica- tion. Neuropathol Appl Neurobiol 2005;31: 62-69.
20. Rousseau A, Nutt CL, Betensky RA, et al. Expression ofoligodendroglial and astrocytic lineage markers in diffuse gliomas: use of YKL-40, ApoE, ASCL1, and NKX2-2. J Neu-ropathol Exp Neurol 2006;65:1149-1156.
21. Aguirre A, Dupree JL, Mangin JM, Gallo V. A functional role for EGFR signaling in myelination and remyelination. Nat Neurosci 2007;10:990-1002.
22. Cassoni P, Senetta R, Castellano I, et al. Caveolin-1 expression is variably displayed in astroglial-derived tumors and absent in oligodendrogliomas: concrete premises for a new reliable diagnostic marker in gliomas. Am J Surg Pathol 2007;31:760-769.
23. Liang Y, Diehn M, Watson N, et al. Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme. Proc Natl Acad SciUSA 2005; 102:5814-5819.
24. Viapiano MS, Bi WL, Piepmeier J, Hockfield S, Matthews RT. Novel tumor-specific isoforms of BEHAB/brevican identified in human malignant gliomas. Cancer Res 2005; 65:6726-6733.
25. Biglari A, Bataille D, Naumann U, et al. Effects of ectopic decorin in modulating intracranial glioma progression in vivo, in a rat syngeneic model. Cancer Gene Ther 2004; 11:721-732.
26. Santra M, Katakowski M, Zhang RL, et al. Protection of adult mouse progenitor cells and human glioma cells by de novo decorin expression in an oxygen- and glucose-deprived cell culture model system. J Cereb Blood Flow Metab 2006;26:1311-1322.
27. Pope WB, Lai A, Nghiemphu P, Mischel P, Cloughesy TF. MR imaging in patients with high grade gliomas treated with bevaci- zumab and chemotherapy. Neurology 2006; 66:1258-1260.
28. Vredenburgh JJ, Desjardins A, Herndon JE, et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 2007;13:1253-1259.
29. Carlson MR, Pope WB, Horvath S, et al. Relationship between survival and edema in malignant gliomas: role of vascular endothe- lial growth factor and neuronal pentraxin 2. Clin Cancer Res 2007;13:2592-2598.
30. Norden AD, Young GS, Setayesh K, et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 2008;70:779-787.
31. Le Jan S, Le Meur N, Cazes A, et al. Characterization of the expression of the hypoxiainduced genes neuritin, TXNIP and IGFBP3 in cancer. FEBS Lett 2006;580:3395-3400.
32. Birnbaum T, Roider J, Schankin CJ, et al. Malignant gliomas actively recruit bone marrow stromal cells by secreting angiogenic cytokines. J Neurooncol 2007;83:241-247.
33. Akabani G, Reardon DA, Coleman RE, et al. Dosimetry and radiographic analysis of 131I-labeled anti-tenascin 81C6 murine monoclonal antibody in newly diagnosed patients with malignant gliomas: a phase II study. J Nucl Med 2005;46:1042-1051.
34. Lee KH, Choi EY, Hyun MS, et al. Association of extracellular cleavage of E-cadherin mediated by MMP-7 with HGF-induced in vitro invasion in human stomach cancer cells. Eur Surg Res 2007;39:208-215.
35. SomasundaramK, ReddySP, VinnakotaK, etal. Upregulation of ASCL1 and inhibition of Notch signaling pathway characterize progressive astrocytoma. Oncogene 2005;24:7073-7083.
36. Tso CL, Freije WA, Day A, et al. Distinct transcription profiles of primary and secondary glioblastoma subgroups. Cancer Res 2006;66:159-167.
37. Karcher S, Steiner HH, Ahmadi R, et al. Different angiogenic phenotypes in primary and secondary glioblastoma. Int J Cancer 2006;118:2182-2189.
38. Lev MH, Ozsunar Y, Henson JW, et al. Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared to conventional contrast enhanced MRI: confounding effect of elevated relative cerebral blood volume of oligoden-drogliomas. AJNR Am J Neuroradiol 2004; 25:214-221.
39. Unger T, Korade Z, Lazarov O, Terrano D, Sisodia SS, Mirnics K. True and false discovery in DNA microarray experiments: tran- scriptome changes in the hippocampus of presenilin 1 mutant mice. Methods 2005; 37:261-273.